Drug news
FDA Advisory Committee recommends vorapaxar for CV Risk - Merck Inc.
The FDA�s Cardiovascular and Renal Drugs Advisory Committee has on 16 January 2014 recommended for approval Zontivity (vorapaxar) from Merck.,. Vorapaxar is the company�s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischaemic attack.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins